Cancer therapies and the problem of me too many

I think its fair to say all large and many small pharmaceutical companies involved in developing cancer drugs are “into immunotherapy”. And nearly all are developing an anti-PD-1 or anti-PD-L1 molecule. The US Food and Drug Administration has already approved two of each. Many will claim they are different and we need to develop more. Such claims ring hollow. With yearly revenues of several billon dollars f or the foreseeable future why should we let Merck and Bristol Myers reap the harvest with pembrolizumab and nivolumab? Anyone who thinks a desire to share in the financial harvest is not the principal or exclusive reason for their development by so many pharmaceutical companies is either (a) naïve, (b) conflicted or (c) both.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research